Small molecular glucokinase activators: has another new anti-diabetic therapeutic lost favour?

UNLABELLED: Glucokinase activators (GKAs) represent one of the leading hopes for the next generation of type 2 diabetes (T2D) therapeutics, showing efficacy in reducing blood glucose and HbA1c levels in animal models of T2D and short-term human trials. While the hypoglycaemic risks of GCK activation...

全面介绍

书目详细资料
Main Authors: Rees, MG, Gloyn, A
格式: Journal article
语言:English
出版: 2013